Improving Results for Express Scripts
The Cigna merger is on track, and we are maintaining our $92 fair value estimate and wide moat rating after a solid quarter for Express Scripts.
Express Scripts (ESRX) reported another solid quarter, and we are maintaining our $92 fair value estimate and wide moat rating. Our valuation represents Cigna’s offer price, which also matches our discounted cash flow-driven valuation for the pharmacy benefit manager. There were no major updates related to the Cigna merger, as this deal recently received Department of Justice approval with no pushback. We expect the transaction to close within the next few months. From an operational standpoint, we believe the new entity will be a formidable force in healthcare and will be able to wield significant pricing power and leverage top-tier scale advantages. Based on the need of payers to control their health benefit plan costs, the efficient management of pharmaceutical expenses will be just as critical as managing medical expenses, such as doctor’s visits and surgeries. As the largest PBM, Express has the scale and expertise to manage drug benefit plans more efficiently than most health plan sponsors. Thus, we believe Cigna will acquire a strong wide-moat asset at a fair price. This dynamic should add significantly to the managed-care organization's competitive advantages over the coming years without any major dilution to its valuation.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Vishnu Lekraj does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.